Objective. To assess the state of pulmonary function in children with cystic fibrosis and to determine the nature and severity of ventilatory disorders based on computerized spirometry data.

Materials and Methods. Pulmonary function was assessed in 64 children with cystic fibrosis aged 5 to 14 years who were receiving inpatient treatment. The control group included apparently healthy children and children with recurrent obstructive bronchitis. Computerized spirometry was performed using a BTL-08 Spiro Pro spirometer with evaluation of the main spirometric parameters (FEV₁, vital capacity, Tiffeneau index, MEF50).

Results. All children with cystic fibrosis demonstrated a reduction in pulmonary function parameters. The combined type of ventilatory impairment was the most frequently observed (62.5%), characterized by the presence of both restrictive and bronchial obstructive components. A statistically significant decrease in FEV₁, vital capacity, Tiffeneau index, and MEF50 was noted compared with children with recurrent obstructive bronchitis and apparently healthy peers (p<0.001). In the majority of patients, marked and severe deviations of pulmonary function indices were identified, reflecting progression of chronic bronchopulmonary involvement.

Conclusion. Children with cystic fibrosis exhibit a pronounced and statistically significant deterioration of pulmonary function parameters, predominantly of a combined ventilatory impairment type. Computerized spirometry is an informative and accessible method for assessing the severity of bronchopulmonary involvement and for monitoring the effectiveness of therapy in this patient population.

Cystic fibrosis, children, pulmonary function

Kashirskaya N.Yu., Petrova N.V., Zinchenko R.A. Clinical efficacy and safety of the combined drug ivacaftor/lumacaftor in patients with cystic fibrosis: a review of international studies. Voprosy sovremennoi pediatrii [Current Pediatrics]. 2021;20(6):558-566.

Pavlinova E. B., Krivtsova L. A., Kirshina I.A. / Methods of investigating pulmonary function in patients with cystic fibrosis. Vestnik SurGU. Meditsina [Bulletin of Surgut State University. Medicine]. No. 16, 2013. pp.17-22.

Simonova O.I., Chernevich V.P., Gorinova Yu. V./ Cystic fibrosis in children: 100 questions and answers [textbook] /2024. --- 112 p.

Chuchalin A. G., ed. Respiratory medicine: a guide: in 5 vols. 3rd ed., rev. and enl. Moscow: PulmoMedia, 2024. -- Vol.2 doi: 10.18093/978-5-6048754-6-9-2024-2.

Shadrina V.V., Zhekaite E.K., Voronkova A.Yu., Sherman V.D., Kondakova Yu.A., Pinegina Yu.S., Poloiko A.A., Furman E.G., Kondratyeva E.I.// Tolerability of the first dose of inhaled mannitol in children with cystic fibrosis / Pul'monologiya [Pulmonology] 2024; 34 (4).

Shamsiev F.M., Azizova N.D., Uzakova Sh.B., Inomov B.N., Mirsalikhova N.Kh., Abdullaeva M.K., Makhpieva G.K. Features of cellular and humoral immunity in children with cystic fibrosis. Journal of modern medicine, No.1, volume1, 2025. pp.1038-1043.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkova P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant В, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis. 2018;(17):153-178. DOI: 10.1016/j.jcf.2018.02.006

Gabbi C., Renieri A., Strandvik B. Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries. J. Infect. 2022;85:318--321. doi: 10.1016/j.jinf.2022.06.006.

Scotet V., L'Hostis C., Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes. 2020;11:589. doi: 10.3390/genes11060589.

Shum B.O.V., Bennett G., Navilebasappa A., Kumar R.K. Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: A case report. BMC Pediatr. 2021;21:154. doi: 10.1186/s12887-021-02609-z.